Table 2.
Preclinical studies of intratumoral (IT) large surface area microparticle docetaxel (LSAM-DTX)
| Tumor type | Cell line | Species/straina | n, range | IT LSAM-DTX dose (mg/kg)b | Cycles adminstered (cycle time) | Reference |
|---|---|---|---|---|---|---|
| Bladder | ||||||
| Human | UM-UC-3 (ATCC® CRL-1749™) | Mouse/nude (Hsd:Athymic Nude-Foxn1nu) | 9-10 | 100 | 1, 2, or 3 (weekly) | [9] |
| Breast | ||||||
| Human | MDA-MB-231 (ATCC® HTB-26 ™) | Mouse/nude (NCr nu/nu) | 5 | 12.5 | 1 | [4] |
| Mouse | 4T1 (ATCC® CRL-2539™) | Mouse/BALB/c (BALB/cAnNHsd) | 7 | 50 | 4 (4 days) | [11] |
| Prostate | ||||||
| Human | PC-3 (ATCC® CRL-1435™) | Mouse/nude (NCr nu/nu (Crl:NU(NCr)-Foxn1nu) | 10 | 37.5, 100 | 1 or 3 (weekly) | [9] |
| Renal | ||||||
| Human | 786-O (ATCC® CRL-1932™) | Rat/Sprague–Dawley (Rag2/Il2rg null) SRG™ | 3 | 20 | 1, 2, or 3 (weekly) | [9] |
| Mouse | Renca (ATCC® CRL-2947™) | Mouse/BALB/c (BALB/cAnNCrl) | 10-15 | 27.5c, 55c | 3 (weekly) | [10] |
aAll studies utilized female animals
bLSAM-DTX dose is approximated based on fixed volume IT injection not adjusted for individual animal body weight
cLSAM-DTX administered as multiple injections IT or IT + peritumoral (IT/PT)